🏛️ Verified NIH Record • Updated 2026-01-23
A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread (NCT02057133)
A Phase 1b Study of Abemaciclib in Combination With Therapies for Patients With Metastatic Breast Cancer
🔵 Active, Not Recruiting Phase1 💊 Investigational Drug / Biologic Sponsor: Eli Lilly and Company
🩺 Plain-English Summary (8th-Grade Level)
This study evaluates the safety of abemaciclib in combination therapies (letrozole, anastrozole, tamoxifen, exemestane, exemestane plus everolimus, trastuzumab, LY3023414 plus fulvestrant, pertuzumab plus trastuzumab with loperamide, or ongoing endocrine therapy) for breast cancer that has spread to other parts of the body.
Who can join: Review the eligibility criteria below.
Location: Highlands Oncology Group - Duplicate 2 — Rogers, Arkansas
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (13 Sites)
- Highlands Oncology Group - Duplicate 2 — Rogers, Arkansas
- University of California - San Diego — La Jolla, California
- Dana Farber Cancer Institute — Boston, Massachusetts
- Mayo Clinic — Rochester, Minnesota
- Columbia University College of Phys & Surgeons — New York, New York
- Memorial Sloan Kettering Cancer Center — New York, New York
- University of North Carolina at Chapel Hill — Chapel Hill, North Carolina
- Providence Cancer Center Oncology Hematology Care — Portland, Oregon
- Univ of Pittsburgh Cancer Inst. (UPCI) — Pittsburgh, Pennsylvania
- Peggy and Charles Stephenson Oklahoma Cancer Center — Nashville, Tennessee
- Tennessee Oncology PLLC — Nashville, Tennessee
- Vanderbilt University Medical Center — Nashville, Tennessee
- South Texas Accelerated Research Therapeutics (START) — San Antonio, Texas
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Breast Neoplasms
- Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49) — Birmingham, Alabama
- (Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer — Phoenix, Arizona
- Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer — Dallas, Texas
- Assessment of Quality of Life and Treatment Times for Patients With Invasive Type Breast Cancer in Martinique — Fort-de-France,
- Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer — Springdale, Arkansas
- The IDEA Study (Individualized Decisions for Endocrine Therapy Alone) — Stanford, California
Explore by condition: All Breast Neoplasms clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.